Literature DB >> 2561961

Cholera toxin as a mucosal adjuvant for respiratory antibody responses in mice.

X P Liang1, M E Lamm, J G Nedrud.   

Abstract

Cholera toxin was investigated as an adjuvant for anti-virus antibody responses in the respiratory mucosa of mice. Two methods of applying cholera toxin were evaluated: oral administration and intranasal administration. Oral immunization with Sendai virus in the presence of cholera toxin effectively primed for respiratory anti-viral antibody responses, whereas oral immunization with Sendai virus alone was ineffective in this respect. In nasal washes, IgA was the predominant anti-viral antibody enhanced by oral cholera toxin; in bronchoalveolar washes, the enhanced anti-viral antibodies included IgG, IgA, and IgM. Effects of direct administration of cholera toxin to the respiratory mucosa on respiratory anti-viral antibody responses depended on the method of anesthesia used during immunization. With inhalation anesthesia (ether), cholera toxin had no adjuvant effect on respiratory antibody responses to coadministered Sendai virus. In contrast, under parenteral anesthesia (i.e., intraperitoneal ketamine), mice which received cholera toxin and Sendai virus via the respiratory tract showed significantly higher anti-viral IgA and IgG antibody titers in nasal washes and IgG antibody in bronchoalveolar washes than mice which received the virus only.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2561961

Source DB:  PubMed          Journal:  Reg Immunol        ISSN: 0896-0623


  5 in total

1.  Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract.

Authors:  J W Simecka; R J Jackson; H Kiyono; J R McGhee
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Oral immunization against Helicobacter pylori.

Authors:  S J Czinn; J G Nedrud
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

3.  Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization.

Authors:  L M Hodge; M Marinaro; H P Jones; J R McGhee; H Kiyono; J W Simecka
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 4.  Interleukin-12 as an adjuvant for induction of protective antibody responses.

Authors:  Dennis W Metzger
Journal:  Cytokine       Date:  2010-07-22       Impact factor: 3.861

5.  Enhancement of humoral immunity by the type II heat-labile enterotoxin LT-IIb is dependent upon IL-6 and neutrophils.

Authors:  Christopher J Greene; John C Hu; David J Vance; Yinghui Rong; Lorrie Mandell; Natalie King-Lyons; Patricia Masso-Welch; Nicholas J Mantis; Terry D Connell
Journal:  J Leukoc Biol       Date:  2016-04-08       Impact factor: 4.962

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.